Unique ID issued by UMIN | UMIN000021004 |
---|---|
Receipt number | R000019658 |
Scientific Title | Effectiveness and safety of tocilizumab therapy for rheumatoid artritis patients |
Date of disclosure of the study information | 2016/02/13 |
Last modified on | 2018/10/17 15:43:23 |
Effectiveness and safety of tocilizumab therapy for rheumatoid artritis patients
Effectiveness of tocilizumab therapy for rheumatoid artjritis patients complicated with interstitial pneumonia.
Effectiveness and safety of tocilizumab therapy for rheumatoid artritis patients
Effectiveness of tocilizumab therapy for rheumatoid artjritis patients complicated with interstitial pneumonia.
Japan |
Rheumatoid arthritis complicated with interstitial pneumonia
Medicine in general | Pneumology | Clinical immunology |
Others
NO
To examine the therapeutic effect of tocilizumab for rheumatoid arthritis patients complicated with interstitial pneumonia.
Efficacy
1)Improvement of disease activity of rheumatoid arthritis
2)Change of severerity of interstitial pneumonia (stage, forced volume capacity)
Observational
Not applicable |
Not applicable |
Male and Female
Rheumatoid arthrit patients with high disease activity and chronic fibrosing interstitial lung disease
Patients who does not agree to tocilizumab therapy
30
1st name | |
Middle name | |
Last name | Shunsuke Mori |
NHO Kumamoto Saishunsou National Hospital
Rheumatology
2659 Suya, Kohshi, Kumamoto Japan
81-96-242-1000
moris@saisyunsou1.hosp.go.jp
1st name | |
Middle name | |
Last name | Shunichi Tsutumiuchi |
2659 Suya, Kohshi, Kumamoto Japan
Secretariat
2659 Suya, Kohshi, Kumamoto Japan
81-96-242-1000
8211sy01@hosp.go.jp
NHO Kumamoto Saishunsou National Hospital
NHO Kumamoto Saishunsou National Hospital
Other
NO
2016 | Year | 02 | Month | 13 | Day |
Unpublished
Among 19 patiets, nine were diagnosed with definite usual interstitia pneumonia (UIP) pattern, eight with possible UIP, one with UIP/nonspecific interstitial pneumonia (NSIP), and one with combined pulmonary fibrosis and emphysema (CPFE).Median CDAI values were significantly imroved during the treatment . ALL patients with possible UIP, CPFE, and UIP/NSIP patterns completed the 96-week treatment and their pulmonary conditions remained stablilized. In contrast, among the patients with UIP pateern, two experienced a worsning of ILD and five withdrew from this study due to the reasons not directly associated with ILD exacerbation.
Completed
2013 | Year | 04 | Month | 01 | Day |
2013 | Year | 04 | Month | 01 | Day |
Considering that the current goal of treatment of progressive fibrosing ILD is stabilization or slow progression of the disease. tocilizumab may represent therapeutic option for RA
patients with this type of ILD.
2016 | Year | 02 | Month | 13 | Day |
2018 | Year | 10 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019658
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |